- Home
- Publications
- Publication Search
- Publication Details
Title
Cetuximab for treating non-small cell lung cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 18, Issue 4, Pages 483-493
Publisher
Informa UK Limited
Online
2018-03-14
DOI
10.1080/14712598.2018.1452906
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MA09.11 Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
- (2017) Benjamin Besse et al. Journal of Thoracic Oncology
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
- (2017) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Same Data; Different Interpretations
- (2016) Bishal Gyawali et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
- (2016) Yong Jia et al. NATURE
- The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
- (2016) Chiara Pozzi et al. NATURE MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy
- (2016) A. M. Trotta et al. Cancer Immunology Research
- PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations
- (2016) Andreas H. Scheel et al. OncoImmunology
- 96O * DETERMINING THE PREVALENCE OF EGFR MUTATIONS IN ASIAN AND RUSSIAN PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (ANSCLC) OF ADENOCARCINOMA (ADC) AND NON-ADC HISTOLOGY: IGNITE STUDY
- (2015) B. Han et al. ANNALS OF ONCOLOGY
- Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)
- (2015) J. Vansteenkiste et al. ANNALS OF ONCOLOGY
- The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients
- (2015) Martino Monteverde et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Concurrent Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer: What Is the Best Regimen?
- (2015) Wilfried Ernst Erich Eberhardt JOURNAL OF CLINICAL ONCOLOGY
- Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (INFORM; C-TONG 0804)
- (2015) Hongyun Zhao et al. Journal of Thoracic Oncology
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
- (2015) Jeffrey D Bradley et al. LANCET ONCOLOGY
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases
- (2015) Vashti Irani et al. MOLECULAR IMMUNOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Necitumumab in Metastatic Squamous Cell Lung Cancer
- (2015) Daniel A. Goldstein et al. JAMA Oncology
- Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours
- (2014) R R Singh et al. BRITISH JOURNAL OF CANCER
- A Phase I Study of Concurrent Individualized, Isotoxic Accelerated Radiotherapy and Cisplatin–Vinorelbine–Cetuximab in Patients With Stage III Non–Small-Cell Lung Cancer
- (2014) Anne-Marie C. Dingemans et al. Journal of Thoracic Oncology
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial
- (2014) David F. Heigener et al. Targeted Oncology
- Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
- (2014) Y. Y. Janjigian et al. Cancer Discovery
- Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung Cancer: SWOG S0536
- (2013) Edward S. Kim et al. Journal of Thoracic Oncology
- Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial
- (2013) Edward S Kim et al. LANCET ONCOLOGY
- Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer
- (2013) Gerald Schmid-Bindert et al. LUNG CANCER
- Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer
- (2013) Jean-Louis Pujol et al. LUNG CANCER
- Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Efficacy and safety outcomes of a randomized, multi-center phase II study investigating
- (2013) Michel M. van den Heuvel et al. RADIOTHERAPY AND ONCOLOGY
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819
- (2012) M. W. Redman et al. CLINICAL CANCER RESEARCH
- A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer
- (2012) Carsten Nieder et al. Radiation Oncology
- Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab
- (2011) Alexandra D. Jensen et al. CANCER
- EGF Receptor Inhibition Radiosensitizes NSCLC Cells by Inducing Senescence in Cells Sustaining DNA Double-Strand Breaks
- (2011) M. Wang et al. CANCER RESEARCH
- 9001 ORAL A Retrospective Subgroup Analysis of EGFR Immunohistochemistry (IHC) Expression by Histo-Score Correlated to Outcomes From the BMS099 1st Line Phase III NSCLC Trial of Cetuximab (Cet) Plus Carboplatin/Taxane
- (2011) T. Lynch et al. EUROPEAN JOURNAL OF CANCER
- Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407
- (2011) Ramaswamy Govindan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324
- (2011) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
- (2011) Kenneth J O'Byrne et al. LANCET ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
- (2011) Robert Pirker et al. LANCET ONCOLOGY
- Cetuximab-based Therapy is Effective in Chemotherapy-naïve Patients with Advanced and Metastatic Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials
- (2011) Ezzeldin M. Ibrahim et al. LUNG
- A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422)
- (2010) A. Jatoi et al. ANNALS OF ONCOLOGY
- Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: A pilot comparative study
- (2010) Jacqueline Duffour et al. EUROPEAN JOURNAL OF CANCER
- Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
- (2010) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Personalized Medicine in Non–Small-Cell Lung Cancer: IsKRASa Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?
- (2010) Patrick J. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer
- (2010) Shirin Khambata-Ford et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Study S0342
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
- (2010) Joel W. Neal et al. Journal of Thoracic Oncology
- Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer
- (2010) Joan H. Schiller et al. Journal of Thoracic Oncology
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- (2010) Federico Cappuzzo et al. LANCET ONCOLOGY
- Concurrent cetuximab and radiotherapy after docetaxel–cisplatin induction chemotherapy in stage III NSCLC: Satellite—A phase II study from the Swedish Lung Cancer Study Group
- (2010) A. Hallqvist et al. LUNG CANCER
- EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer
- (2009) M Varella-Garcia et al. JOURNAL OF CLINICAL PATHOLOGY
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
- (2009) T. Fojo et al. JNCI-Journal of the National Cancer Institute
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- Dual Inhibition of the Epidermal Growth Factor Receptor Pathway with Cetuximab and Erlotinib: A Phase I Study in Patients with Advanced Solid Malignancies
- (2009) M. J. Guarino et al. ONCOLOGIST
- Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses
- (2008) P. Bruhns et al. BLOOD
- IncreasedEGFRGene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy
- (2008) Fred R. Hirsch et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More